NESS-ZIONA, Israel I April 03, 2025 I Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming ...
New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically ...
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a revised operating plan as it evaluates a range of ...
The following is a summary of “Trans-omics landscape of systemic vasculitis identified matrix metalloproteinase 12 as a novel ...
Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...
D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps a Buy rating on the shares after the ...
Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) DUBLIN, Ireland and OXFORD, ...
After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...
Carisma Therapeutics Inc. ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives while reducing ...
Cardiac macrophages in newborn mice promoted heart cell proliferation after injury, offering a potential approach to ...
This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback